Here, we found that the expression of ZRF1 mRNA is increased in advanced disease stages and in tumors, with the most common genetic alterations associated with poor prognosis in neuroblastoma, such as MYCN amplification, gain of chromosome 17q, and loss of 1p36. This evidence concerns the gene MYCN and neuroblastoma.